Glaxo CEO Walmsley on Tech Partnerships, Tesaro Acquisition, Pricing

The video discusses GlaxoSmithKline's (GSK) strategic focus on innovation, performance, and trust, highlighting their investments in AI and technology to enhance healthcare. It covers the acquisition of Tesaro to boost cancer treatment options, particularly in ovarian cancer, and the expansion of their oncology portfolio. GSK's advancements in HIV treatment, including two-drug regimens and long-acting injectables, are also discussed. The video concludes with GSK's commitment to financial stability, maintaining dividends, and advocating for drug pricing transparency.

What are the expected outcomes of GSK's new oncology medicines?

How does GSK plan to balance innovation with maintaining dividends?

What is GSK's approach to drug pricing transparency?